Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D, Pfeiler G, Bartsch R, Wette V, Pichler A, Petru E, Dubsky PC, Bago-Horvath Z, Fesl C, Rudas M, Ståhlberg A, Graf R, Weber S, Dandachi N, Filipits M, Gnant M, Balic M, Heitzer E.
Zhou Q, et al. Among authors: dandachi n.
Clin Cancer Res. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231.
Clin Cancer Res. 2022.
PMID: 34862246
Free PMC article.